Literature DB >> 24942271

Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study.

C L Martyn-Simmons1, W M C Rosenberg, R Cross, T Wong, C H Smith, J N W N Barker.   

Abstract

BACKGROUND: Methotrexate is a cost-effective systemic treatment for moderate-to-severe psoriasis, but the perceived risk of associated liver fibrosis prevents optimal use. Procollagen III aminoterminal propeptide (PIIINP) is a widely adopted noninvasive biomarker of liver fibrosis; however, its clinical utility is narrow owing to limited evidence of performance and the need for serial measurement. The Enhanced Liver Fibrosis (ELF) assay is a validated biomarker of liver fibrosis.
OBJECTIVES: To evaluate the diagnostic accuracy of the ELF test compared with PIIINP for the diagnosis of liver fibrosis in a cohort of patients with psoriasis treated with methotrexate.
METHODS: A retrospective cohort study comparing the diagnostic accuracy of PIIINP and ELF in detecting liver fibrosis in patients treated with methotrexate. Liver biopsy was the reference standard.
RESULTS: Twenty-seven patients were identified and included in the study. The diagnostic accuracies [area under the receiver operating curve (AUROC)] of serial PIIINP and serial ELF were 0·589 [95% confidence interval (CI) 0·379-0·800] and 0·643 (95% CI 0·391-0·895), respectively, for mild fibrosis; and 0·576 (95% CI 0·237-0·916) and 0·674 (95% CI 0·421-0·927) for at least moderate fibrosis. The AUROC values for single PIIINP and single ELF were 0·582 (95% CI 0·363-0·801) and 0·693 (95% CI 0·482-0·904), respectively, for mild fibrosis; and 0·667 (95% CI 0·363-0·971) and 0·806 (95% CI 0·564-1·000) for at least moderate fibrosis.
CONCLUSIONS: This pilot study suggests that ELF may be at least equivalent or possibly superior to PIIINP in the detection of liver fibrosis in patients with psoriasis treated with methotrexate, and supports further investigations into the performance of ELF in this clinical setting.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24942271     DOI: 10.1111/bjd.12782

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  Significance of liver biopsy for the evaluation of methotrexate-induced liver damage in patients with rheumatoid arthritis.

Authors:  Tatsuya Osuga; Yoshihiro Ikura; Chikara Kadota; Seiichi Hirano; Yasuhiro Iwai; Takanobu Hayakumo
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV/HCV Infected Patients.

Authors:  Enass A Abdel-Hameed; Susan D Rouster; Shyam Kottilil; Kenneth E Sherman
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

3.  Noninvasive proteomic biomarkers for alcohol-related liver disease.

Authors:  Lili Niu; Maja Thiele; Philipp E Geyer; Ditlev Nytoft Rasmussen; Henry Emanuel Webel; Alberto Santos; Rajat Gupta; Florian Meier; Maximilian Strauss; Maria Kjaergaard; Katrine Lindvig; Suganya Jacobsen; Simon Rasmussen; Torben Hansen; Aleksander Krag; Matthias Mann
Journal:  Nat Med       Date:  2022-06-02       Impact factor: 87.241

4.  Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.

Authors:  Felien T M Busger Op Vollenbroek; Carine J M Doggen; René W A Janssens; Hein J Bernelot Moens
Journal:  PLoS One       Date:  2018-03-23       Impact factor: 3.240

5.  Hepascore predicts liver outcomes and all-cause mortality in long-term methotrexate users: A retrospective cohort study.

Authors:  Zhengyi Wang; Yi Huang; Hans Nossent; Jonathan J Chan; Leon A Adams; John Joseph; Wendy Cheng; George Garas; Gerry MacQuillan; Gary P Jeffrey
Journal:  JGH Open       Date:  2020-10-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.